COMP <GO>
NVAX vs IMCR // REVENUE GROWTH (YOY)
Novavax Inc. (NASDAQ) VS. Immunocore Holdings plc (NASDAQ) • 15-METRIC TALLY: NVAX 5
— IMCR 4
▲ REVENUE GROWTH (YOY) LEADER: NVAX
LAST: $10.08 (-3.72%) • MKT CAP: $1.73B
revenue-growth
64.70%
LAST: $30.49 (-2.49%) • MKT CAP: $1.61B
revenue-growth
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NVAX VS. IMCR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NVAX | IMCR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 93.50% | 96.00% | -2.50 | IMCR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | -35.00% | +120.00 | NVAX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -14.17% | -0.93% | -13.24 | IMCR | /fcf-yield <GO> |
| Operating Margin | 40.30% | -11.30% | +51.60 | NVAX | /operating-margins <GO> |
| Net Profit Margin | 39.20% | -8.90% | +48.10 | NVAX | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 64.70% | 29.00% | +35.70 | NVAX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 1.40 | -1.20 | IMCR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 5/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.3 | 50.8 | -2.50 | IMCR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 3.5x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.73B | $1.61B | $116.6M | NVAX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NVAX REV | IMCR REV | NVAX GROSS % | IMCR GROSS % | NVAX FCF | IMCR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.12B | $400.0M | 93.5% | 98.0% | -$244.6M | -$15.1M |
| FY 2024 | $682.2M | $310.2M | 70.3% | 98.0% | -$87.3M | $20.9M |
| FY 2023 | $983.7M | $249.4M | — | — | -$714.0M | $2.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NVAX // BETA —
IMCR // BETA —